Kerwin Medical Center

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease15 trials
• Frontotemporal dementia1 trial
• Lewy body dementia1 trial

Phase

• Phase 38 trials
• Phase 25 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Active, not recruiting9 trials
• Completed3 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company7 trials
• Hoffmann-La Roche2 trials
• Acumen Pharmaceuticals1 trial
• AriBio Co., Ltd.1 trial
• Biogen1 trial
• and 3 more

Running trials

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

  Contact: Alka Khera (principal investigator)

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

  NCT06750432· Phase 1· ProMis Neurosciences, Inc· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

  NCT06335173· Phase 2· Acumen Pharmaceuticals· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

• Active, not recruiting

  Clinical Trial on Agitation in Alzheimer's Dementia

  NCT05543681· Phase 2· IGC Pharma, LLC· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

  NCT01760005· Phase 2/3· Washington University School of Medicine· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Lewy body dementia1 recruiting

Closed trials

• Completed

  A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

  NCT06538116· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· Phase 2· Eli Lilly and Company· Source